

EPS 39x



41613168111 lonza.com Basel, SWITZERLAND Inc 1897 MGMT owns --

Lonza Group AG is engaged in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Biologics, Small Molecules, Cell and Gene, Capsule and Health Ingredients, and Corporate. The Biologics segment serves as contract development and manufacturing partner for biopharmaceuticals, catering customers for all clinical and commercial manufacturing needs throughout the product lifecycle. The Small Molecules segment offers small molecule drug substances and intermediates related services. The Cell and Gene segment includes the Cell and Gene Technologies and Bioscience businesses. The Capsule and Health Ingredients segment provides innovative capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical companies. The Corporate segment refers to finance and accounting, legal, communication, information technology, and human resources functions. The company was founded on October 27, 1897 and is headquartered in Basel, Switzerland. [LESS](#)

Europe Long -0.69% in 0.9 WKS

OH -1% LOG (Fixed) PRICE

ANNUAL - DEC END	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025 Estimate	2026 Estimate
EPS CHF	5.31	10.42	7.51	10.20	11.68	39.65	16.37	8.88	8.93	16.37	83%
CASH FLOW/SHR CHF	13.21	12.49	14.51	13.21	15.21	16.38	13.97	19.26		Earnings Growth Rate	
PRETAX MARGIN %	9%	12%	15%	17%	18%	15%	23%	12%	12%	2022-24	-47% (23 Stability)
RETURN ON EQUITY %	13%	16%	11%	10%	11%	8%	12%	7%	7%	2020-24	-6% (70 Stability)
SALES % CHANGE	9%	10%	22%	-24%	7%	20%	15%	8%	-2%	COMP RATING	70
SALES (MIL) CHF	4,132	4,548	5,542	4,207	4,508	5,409	6,223	6,717	6,574	SMR RATING	D
WEEKLY	Dec 20	Dec 27	Jan 3	Jan 10	Jan 17	Jan 24	Jan 31	Feb 7	Feb 11	DEBT %	2022-24
DATAGRAPH RATING	57	57	55	61	62	60	67	67	69	TAX RATE	2022-24
AVG DAILY VOL (000)	137	136	136	133	135	137	147	147	145	BACKLOG	2022-24
UP/DOWN VOLUME	1.2	1.2	1.2	1.2	1.4	1.6	1.4	1.6	1.7	R & D	--
ACCUM/DIST RATING	1	0	0	9	25	45	30	30	29	Div CHF	4.00 (0.7%)
RELATIVE STRENGTH	77	83	85	86	87	81	73	78	79	BETA	0.98(18.00)
GROUP RANK	32	32	49	46	44	61	48	37	33	2024 EMPLOYEES	18,686 (4%)



FINANCIALS	Mar 21	Jun 21	Sep 21	Dec 21	Mar 22	Jun 22	Sep 22	Dec 22	Mar 23	Jun 23	Sep 23	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25	Sep 25	Dec 25	P/E
EPS (CHF)		4.29		35.35		6.63		9.73		5.52		3.38		4.78		4.15		6.95e		9.47e	2025 Est.: 37.2
EPS % CHANGE		-33%		+570%		+55%		-72%		-17%		-65%		-13%		+23%		+45%e		+128%e	2026 Est.:
SALES (MIL CHF)		2,542.0		2,867.0		2,982.0		3,241.0		3,078.0		3,639.0		3,057.0		3,517.0		3,518.9e		4,162.0e	5-yr High: 70
SALES % CHANGE		-17%		+100%		+17%		+13%		+3%		+12%		-1%		-3%		+15%e		+18%e	5-yr Low: 11
EPS % SURPRISE		+44.0%		-29.1%		-0.2%		+3.8%		-8.9%		-8.4%		+38.3%		+16.7%					vs Ind. Avg:
FUNDS	1,819	1,848	1,892	1,983	2,013	2,116	2,168	2,199	2,200	2,231	2,208	2,047	2,208	2,226	2,242	2,284					
SHARES HELD BY FUNDS	32M	32M	32M	33M	33M	32M	33M	33M	34M	34M	33M	31M	31M	31M	30M	31M					